Prelude Therapeutics (PRLD) Stock Chart & Stock Price History $0.81 +0.01 (+1.25%) As of 07/3/2025 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Prelude Therapeutics Stock Price Performance The Prelude Therapeutics (PRLD) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 77.50%, with a year-to-date return of -36.47%. In the past month, the stock has decreased 21.36%, reflecting recent market activity. As of the latest close, Prelude Therapeutics traded at $0.81 with a market cap of $45.73 million and volume of 87,143 shares. Receive PRLD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.25%1 Month Performance-21.36%3 Month Performance+20.00%Year-To-Date Performance-36.47%1 Year Performance-77.50% PRLD Stock Chart for Sunday, July, 6, 2025 PRLD Chart by TradingView Prelude Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/04/2025$0.81$0.81$0.82$0.7887,143 shs$45.73 million07/03/2025$0.80$0.81+1.25%$0.82$0.7887,143 shs$45.73 million07/02/2025$0.80$0.80$0.82$0.7860,459 shs$45.17 million07/01/2025$0.81$0.80-1.16%$0.84$0.7899,164 shs$45.17 million06/30/2025$0.79$0.81+3.07%$0.83$0.77110,335 shs$45.70 million06/27/2025$0.86$0.79-8.69%$0.86$0.771.85 million shs$44.34 million06/26/2025$0.85$0.86+0.61%$0.86$0.80170,785 shs$48.56 million06/25/2025$0.88$0.85-2.43%$0.89$0.78169,477 shs$48.26 million06/24/2025$0.84$0.88+4.30%$0.89$0.8467,967 shs$49.47 million06/23/2025$0.86$0.84-2.38%$0.86$0.8269,982 shs$47.43 million Get the Latest News and Ratings for PRLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/20/2025$0.86$0.86-0.07%$0.95$0.85108,690 shs$48.58 million06/19/2025$0.86$0.86$0.95$0.84170,107 shs$48.62 million06/18/2025$0.93$0.86-7.16%$0.95$0.84170,107 shs$48.62 million06/17/2025$0.97$0.93-4.76%$1.02$0.9361,442 shs$52.37 million06/16/2025$0.96$0.97+1.44%$1.02$0.9751,233 shs$54.99 million06/13/2025$1.04$0.96-7.68%$1.02$0.9271,164 shs$54.21 million06/12/2025$1.10$1.04-5.02%$1.09$1.0087,405 shs$58.72 million06/11/2025$1.08$1.10+1.39%$1.16$1.06224,033 shs$61.82 million06/10/2025$1.18$1.08-8.47%$1.25$1.03381,120 shs$60.98 million06/09/2025$1.03$1.18+14.56%$1.20$1.04365,898 shs$66.62 million06/06/2025$0.98$1.03+5.30%$1.04$0.94122,504 shs$58.15 million06/05/2025$1.00$0.98-2.17%$1.03$0.9382,412 shs$55.23 million Related Companies AC Immune Stock Price Chart Tiziana Life Sciences Stock Price Chart Citius Oncology Stock Price Chart ProKidney Stock Price Chart Editas Medicine Stock Price Chart 4D Molecular Therapeutics Stock Price Chart CytomX Therapeutics Stock Price Chart Organigram Global Stock Price Chart Ventyx Biosciences Stock Price Chart Galena Biopharma Stock Price Chart Receive PRLD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PRLD) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts